Tenaya Therapeutics (NASDAQ:TNYA) lost over half its market capitalization on Tuesday after the cardiac drug developer announced initial results from its Phase 1b/2 MyPEAK-1 clinical trial for its ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...

(RTTNews) - South San Francisco, California-based Tenaya Therapeutics, Inc. (TNYA), a clinical-stage biotechnology company, has priced its underwritten public offering of 75 million units at $0.70 ...

Tenaya Therapeutics is a clinical-stage biotechnology ... while the worst include Trade Desk and West Pharmaceutical. We sell different types of products and services to both investment ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on TNYA: Tenaya Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Get Free Report) have been given a consensus rating of “Buy” by the six research firms that are covering the firm, Marketbeat.com reports.

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...